PATEL

 Representative Publications:

 

1.    Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate Jr. C, Posener J, Lee H, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry, 2000, 157:6, 982-986.

 

2.     Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: Need for action. General Hospital Psychiatry, 2000, 22, 224-235.

 

3.    Patel JK. Bipolar I disorder with psychosis: A case report. CME Clinical Lessons in Institutional Psychiatry, 2000, 1(1):7-9.

 

4.    Patel JK, Caplan B, Green AI, Tamminga C. First Episode Psychosis: Critical management issues during the first two years. Harvard Review of Psychiatry, 2001, 9(1): 33-41.

 

5.    Zarate Jr. C & Patel JK. Sudden Cardiac Death and Antipsychotic Drugs: Do We Know Enough? (Commentary) Arch Gen Psych, 2001, 58(12):1168-1171.

 

6.    Niznikiewicz MA, Patel JK, McCarley R, Sutton J, Chau DT, Wojcik J, Green AI. “Clozapine Action on Auditory P3 Response in Schizophrenia. Schizophrenia Research, 2005, Jul 1; 76(1): 119-121.

 

7.    Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK; HGDH Research Group. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research, 2005, Oct 15;78(2-3):161-9.

 

8.    Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe R, Stroup TS, Lieberman JA. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research, 2005, Dec 1; 80(1):9-18.

 

9.    Mansour HA, Talkowski ME, Wood J, Pless L, Bamne M, Chowdari KV, Allen M, Bowden CL, Calabrese J, El-Mallakh RS, Fagiolini A, Faraone SV, Fossey MD, Friedman ES, Gyulai L, Hauser P, Ketter TA, Loftis J, Marangell LB, Miklowitz DJ, Nierenberg AA, Patel JK, Sachs G, Sklar P, Smoller J, Thase M, Frank E, Kupfer DJ, Nimgaonkar VL. Serotonin Gene Polymorphisms and Bipolar I Disorder: Focus on the Serotonin Transporter. Annals of Med, 2005; 37:590-602.

 

10.    Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington N, Nierenberg AA, Sachs GS, Thase M. Predictors of recurrence in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry, 2006 Feb; 163(2):217-24

11.    Chakos MH, Glick ID, Miller AL, Hammer MB, Miller DD, Patel JK, Tapp A, Keefe RSE, Rosenheck R. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial. Psychiatric Services, 2006, 57:1094-1101.

 

12.    Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel JK, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. New England Journal of Medicine, 2007, 356(17): 1711-22.

 

13.    Perlick DA, Rosenheck RA, Miklowitz DJ, Chessick C, Wolff N, Kaczynski R, Ostacher MJ, Patel JK, Desai R and the STEP-BD Family Experience Collaborative Study Group. Prevalence and correlates of burden in caregivers of bipolar patients. Bipolar Disorders, 2007, 9:262-273.

 

14.    Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Kogan JN, Sachs GS, Thase ME, Calabrese JR, Marangell LB, Ostacher MJ, Patel JK, Thomas MR, Araga M, Gonzalez JM, Wisniewski SR. Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry, 2007, 164:1340-1347.

 

15.    Goff DC, Lamberti JS, Leon AC, Green MF, Miller A, Patel JK, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacolgy, 2008, 33:465-472. epub 9 May 2007; doi:10.1038/sj.npp.1301444.

 

16.    Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller del D, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA; CATIE Investigators. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res, 2008, 100(1-3):39-52. Epub 2008 Jan 11.

 

17.    Ostacher MJ, Nierenberg AA, Iosifescu DV, Eidelman P, Lund HG, Ametrano RM, Kaczynski R, Calabrese J, Miklowitz DJ, Sachs GS, Perlick DA; STEP-BD Family Experience Collaborative Study Group. Correlates of subjective and objective burden among caregivers of patients with bipolar disorder. Acta Psychiatr Scand. 2008, 118(1):49-56.

 

18.    Sklar P, Smoller JW, Fan J, & 79 Collaborators. Whole-genome association study of bipolar disorder. Mol Psychiatry, 2008, 13(6):558-69. Epub 2008 March 4.

 

19.    Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA; CATIE investigators (56 collaborators).Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br. J Psychiatry, 2008; 193(1):37-43.

 

20.    El-Mallakh RS, Ghaemi SN, Sagduyu K, Thase ME, Wisniewski SR, Nierenberg AA, Zhang HW, Pardo TA, Sachs G; STEP-BD Investigators (61 collaborators).Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J. Affect Disor. 2008; 111(2-3):373-7.

 

21.    Miller del D, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup BL, Lieberman JA; CATIE Investigators (57 collaborators).Extrapyramidal side-effects of antipsychotics in randomized trial. Br. J Psychiatry, 2008; 193(4):279-88.

 

22.    Fan J, Ionita-Laza I, McQueen MB, Devlin B, Purcell S, Faraone SV, Allen MH, Bowden CL, Calabrese JR, Fossey MD, Friedman ES, Gyulai L, Hauser P, Ketter TB, Marangell LB, Miklowitz DJ, Nierenberg AA, Patel JK, Sachs GS, Thase ME, Molay FB, Escamilla MA, Nimgaonkar VL, Sklar P, Laird NM, Smoller JW. Linkage Disequilibrium Mapping of the Chromosome 6q21-22.31. Bipolar I Disorder Susceptibility Locus. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, epub: 23 March 2009, DOI: 10.1002/ajmg.b.30942 (in press).

 

23.    Patel JK, Buckley PF, Hamer RM, Woolson HS, McEvoy JP, Perkins D, Lieberman JA. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFÉ study. Schizophrenia Research, 2009, 111:9-16.

 

24.    Mansour HA, Talkowski ME, Wood J, Chowdari KV, McClain L, Prasad K, Montrose D, Fagiolini A, Friedman ES, Allen MH, Bowden CL, Calabrese J, El-Mallakh RS, Escamilla M, Faraone SV, Fossey MD, Gyulai L, Loftis JM, Hauser P, Ketter TA, Marangell LB, Miklowitz DJ, Nierenberg AA, Patel JK, Sachs GS, Sklar P, Smoller JW, Laird N, Keshavan M, Thase ME, Axelson D, Birmaher B, Lewis D, Monk T, Frank E, Kupfer DJ, Nimgaonkar VL. Association study of twenty-one circadian genes with bipolar 1 disorder, schizoaffective disorder and schizophrenia. Bipolar Disorders (In Press).

 

Multi-site study publications (with authorship acknowledgement):

 

25.    Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS, and HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004 Feb 1:66(2-3): 125-35.

 

26.    Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, Sachs GS, Nierenberg AA, Thase ME, Pollack MH; STEP-BD Investigators. Anxiety disorder co morbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry, 2004 Dec; 161(12): 2222-2229.

 

27.    Kogan JN, Otto MW, Bauer MS, Dennehy EB, Miklowitz DJ, Zhang HW, Ketter T, Rudorfer MV, Wisniewski SR, Thase ME, Calabrese J, Sachs GS; STEP-BD Investigators. Demographic and diagnostic characteristics of the first 1000 patients enrolled in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Bipolar Disord. 2004 Dec; 6(6): 460-9.

 

28.    Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, Nierenberg AA, Calabrese JR, Sachs GS, Pollock MH; STEP-BD Investigators. Pharmacotherapy for bipolar disorder and co morbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004 Oct; 24(5): 512-520.

 

29.    Perlis R, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, Bowden CL, Sachs GS, and Nierenberg AA for the STEP-BD Investigators. Long-term implications of early onset in bipolar disorder: Data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry, 2004; 55:875-881.

 

30.    Marangell LB, Martinez JM, Ketter TA, Bowden CL, Goldberg JF, Calabrese JR, Miyahara S, Miklowicz DJ, Sachs GS and Thase ME for the STEP-BD Investigators. Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disorder, 2004; 6:139-143.

 

31.    Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA & the HGDH Research Group. Comparative effect of atypical and conventional drugs on neurocognition in first-episode psychosis: A randomized, double- blind trial of olanzapine versus haloperidol. American J Psychiatry, 2004; 161:985-995.

 

32.     Lembke A, Miklowicz DJ, Otto MW, Zhang H, Wisniewski SR, Sachs GS, Thase ME, Ketter TA; STEP-BD Investigators. Psychosocial service utilization by patients with bipolar disorders: data from the first 500 participants in the Systematic Treatment Enhancement Program. J Psychiatr Pract, 2004; Mar: 10(2)81-7.

 

33.     Weiss RD, Ostacher MJ, Otto MW, Calabrese JR, Fossey M, Wisniewski SR, Bowden CL, Nierenberg AA, Pollack MH, Salloum IM, Simon NM, Thase ME, Sachs GS; for STEP-BD Investigators. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry, 2005; Jun 66(6):730-5

 

34.    Nierenberg AA, Miyahara S, Spencer T, Wisniewski SR, Otto MW, Simon N, Pollack MH, Ostacher MJ, Yan L, Siegel R, Sachs GS; STEP-BD Investigators. Clinical and Diagnostic implications of lifetime attention-deficit/hyperactivity disorder co morbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psych. 2005; Jun 57(11):1467-73.

 

35.    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New Eng J Med 2005;(353):1209-1233.

36.    Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen